This post was shared from the's RSS feed

Kyowa Hakko has participated in the International Society of Sports Nutrition (ISSN) Conference, according to a press release, highlighting products IMMUSE and EYEMUSE.

IMMUSE is Lactococcus lactis strain plasma (LC-plasma), discovered by Kyowa Hakko’s parent company Kirin Holding Company. It acts by activating plasmacytoid dendritic cells (pDC), which in turn activate NK, Killer-T, Helper-T, and B cells, providing immune support. IMMUSE is backed by two safety studies and nine efficacy studies.

Dr. Shintaro Ichikawa, Director of Technical Affairs at Kyowa Hakko USA, said in the press release: “It is well known that prolonged high intensity exercise decreases immune function and increases the risk of upper respiratory tract infections (URTI). It is a serious problem for athletes because not only are URTIs unpleasant, they will also reduce training efficiency. There is emerging evidence that has shown oral intake of LC-Plasma activates pDC and provides immune support. This novel approach to enhance the immune system may improve the experience of continuous high intensity training.”

Related: NBA Basketball Players Found to Have Low O3I Levels
Kyowa Hakko Launches “Breathe” Campaign
The Active Nutrition Opportunity

EYEMUSE debuted at ISSN. It is a heat-treated paraprobiotic, Lacticaseibacillus paracasei KW3110, which has been shown to support healthy eye function by stimulating the immune cells that produce regulatory cytokines such as IL-10, which may help reduce digital stress-related eye fatigue.

Interested in active nutrition? The Naturally Informed event Active Nutrition: Mastering the Market took place June 29-30. If you missed it, no worries—it’ll be available on demand in the first week of July. Register at

The post Kyowa Hakko Debuts Product at Sports Nutrition Conference appeared first on WholeFoods Magazine.

Original post at